STAAR Surgical stock barely flinched after earnings, slipping just 0.3% to about US$25 even though the quarter marked a clean break from last year’s bruising losses. The market came in wary after a rough 90 days for the stock and a history of red ink. The headline this time is simple. Q2 brought a clear return to profit with net income of US$8.1m and basic earnings per share of US$0.16, backed by US$93.5m of sales and a cash pile of US$181.5m with no debt.

Is STAAR Surgical a genuine discount, with a DCF estimate above the current US$25 share price, or just expensive on rich P/S multiples? Compare the story for yourself on our valuation analysis for STAAR Surgical

Q2 2026 Earnings Summary

• Revenue, Q2 2026 vs. Q2 2025: US$93.5m vs….